Protocol Ledger

NCT07570316 · Phase III · RECRUITING

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

Interventional Phase III clinical trial protocol NCT07570316 sponsored by argenx in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-10 Enrollment: 230 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07570316
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)230 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07570316
Protocol FieldVerified Registry Value
NCT IdentifierNCT07570316
Consolidated Lead Sponsorargenx
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment230 participants (ESTIMATED)
Registered Start Date2026-06-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07570316
Hospital Research SiteLocationSite Profile
University of Michigan Rogel Cancer CenterAnn Arbor, MIOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI